Abbott Laboratories $ABT Shares Purchased by Groupe la Francaise

Key Points

• Groupe la Française increased its Abbott Laboratories stake by 22.3% in the second quarter, acquiring 10,556 additional shares and bringing its holdings to 57,813 shares valued at approximately $5.25 million.
• Abbott reported quarterly EPS of $1.31 and revenue of $12.59 billion, exceeding analyst expectations; revenue rose 13% year over year. The company issued 2026 EPS guidance of $5.45–$5.60.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $119.50, versus the stock’s reported price of $108.29. Abbott also pays a quarterly dividend of $0.63, yielding about 2.3% annually.

Groupe la Francaise raised its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 22.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 57,813 shares of the healthcare product maker's stock after buying an additional 10,556 shares during the quarter. Groupe la Francaise's holdings in Abbott Laboratories were worth $5,248,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ABT. Nia Impact Advisors LLC grew its position in shares of Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker's stock valued at $504,000 after purchasing an additional 79 shares during the period. Riggs Asset Managment Co. Inc. boosted its holdings in shares of Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker's stock valued at $140,000 after buying an additional 88 shares during the period. Eley Financial Management Inc raised its holdings in shares of Abbott Laboratories by 0.9% during the fourth quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker's stock worth $1,355,000 after acquiring an additional 92 shares during the period. Kelleher Financial Advisors boosted its stake in Abbott Laboratories by 2.9% in the 3rd quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker's stock worth $442,000 after purchasing an additional 93 shares during the period. Finally, Copley Financial Group Inc. raised its stake in shares of Abbott Laboratories by 2.1% in the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker's stock valued at $556,000 after purchasing an additional 93 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $108.29 on Tuesday. The company has a market capitalization of $187.38 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.01 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The stock's 50 day moving average is $104.74 and its 200-day moving average is $100.00.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories's payout ratio is currently 81.55%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABT. Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target for the company. Royal Bank Of Canada reissued an "outperform" rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating for the company in a report on Wednesday, May 27th. Bank of America decreased their price target on Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Finally, Citigroup boosted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.